SURPASSing the current dogma: is our framework shifting?

Abstract

In their article in The Lancet Diabetes and Endocrinology, Tadej Battelino and colleagues1 report on a dedicated substudy of the parent SURPASS-3 randomised clinical trial, in which all three groups given the dual GLP-1 and GIP, tirzepatide (5 mg, 10 mg, or 15 mg weekly doses), had significantly greater reductions in HbA1c (estimated treatment difference [ETD] –0·59% to –1·04%, p<0·0001) and bodyweight (ETD –9·8 to –15·2 kg, p<0·0001) at 52 weeks than did the insulin degludec group in participants who were insulin-naive with type 2 diabetes.